Anzeige
Mehr »
Mittwoch, 27.08.2025 - Börsentäglich über 12.000 News
Patentschutz bis in die 2040er - Biotech-Geheimtipp vor möglichem Fast-Track-Durchbruch in den USA!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2N7N8 | ISIN: KYG4818G1010 | Ticker-Symbol: 6IB
Frankfurt
27.08.25 | 15:59
10,200 Euro
-1,92 % -0,200
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
INNOVENT BIOLOGICS INC Chart 1 Jahr
5-Tage-Chart
INNOVENT BIOLOGICS INC 5-Tage-Chart
RealtimeGeldBriefZeit
9,95010,10020:12
9,95010,10020:13

Aktuelle News zur INNOVENT BIOLOGICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
12:30Innovent Biologics estimates ~50% jump in 2025 revenue4
INNOVENT BIOLOGICS Aktie jetzt für 0€ handeln
12:30Innovent Biologics reports interim results3
12:17INNOVENT BIO Swings Loss into Profit of RMB834M in 1H4
12:08Innovent Biologics: Innovent Announces 2025 Interim Results and Business Updates1.162Robust revenue growth and substantial profit improvement Continued exceptional executions under a clear roadmap of dual-driven growth and global innovation SAN FRANCISCO and SUZHOU...
► Artikel lesen
11:30INNOVENT BIO (01801): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 JUNE 20251
DiINNOVENT BIO (01801): LIST OF DIRECTORS AND THEIR ROLE AND FUNCTION5
DiINNOVENT BIO (01801): APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF THE STRATEGY COMMITTEE-
MoInnovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2a-bias) in Squamous Non-Small Cell Lung Cancer95SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed...
► Artikel lesen
13.08.ALI HEALTH, INNOVENT BIO Forge Strategic Co-op on Disease Mgmt, Digital Marketing11
07.08.INNOVENT BIO Expects 1H Total Product Rev. RMB5.2B+, Up 35% YoY3
07.08.INNOVENT BIO (01801): INSIDE INFORMATION ANNOUNCEMENT - UPDATE ON THE COMPANY'S PRODUCT REVENUE IN THE SECOND QUARTER OF 20254
05.08.Innovent Biologics: Innovent Receives U.S. FDA Approval for IND Application of Oral GLP-1R Agonist IBI303280SAN FRANCISCO and SUZHOU, China, Aug. 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
► Artikel lesen
04.08.INNOVENT BIO (01801): DATE OF BOARD MEETING2
17.07.Nature Medicine Published Phase 1 Results of Innovent Biologics' Anti-CLDN18.2 ADC (IBI343) in Patients with Advanced Gastric/Gastroesophageal Junction Adenocarcinoma127SAN FRANCISCO and SUZHOU, China, July 16, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that...
► Artikel lesen
04.07.INNOVENT BIO (01801): NEXT DAY DISCLOSURE RETURN1
04.07.INNOVENT BIO (01801): COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE1
30.06.INNOVENT BIO (01801): GRANT OF SHARE OPTIONS AND RESTRICTED SHARES2
30.06.Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide61
27.06.With China approval, Lilly and Innovent's mazdutide breaks into new class for GLP-1 obesity drugs23
27.06.Innovent's Mazdutide receives approval for chronic weight management in China2
Weiter >>
76 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1